SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

COGT

Cogent Biosciences, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

This quarter's results are backward-looking and immaterial for a pre-revenue biotech awaiting two PDUFA catalysts. The stock will trade on the binary outcomes of FDA approvals for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30), not on a $0.04 EPS miss on an expected negative number. Monitor street-side analyst updates on launch revenue estimates and any FDA advisory committee briefing documents ahead of the PDUFA dates.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$41.53
T+0 close · Aug 10, 2026 · via day close
Latest settled
−25.21%
T+60 · $31.06
Vs SPY
−22.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $41.53entry
  2. T+1 · 3mo ago −6.81%α −6.49% · $38.70
  3. T+5 · 3mo ago −8.81%α −8.77% · $37.87
  4. T+20 · 2mo ago −15.05%α −14.13% · $35.28
  5. T+60 · 14d ago −25.21%α −22.79% · $31.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cogent Biosciences reported Q2 2026 net loss of $96.4 million (EPS $-0.60 vs consensus $-0.56, a 6.2% miss) as R&D and G&A expenses scaled for commercial readiness ahead of dual PDUFA dates for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30). Cash position of $792.3 million plus $73.6 million in post-quarter ATM proceeds provides runway into late 2028, but the quarter's results are secondary to the binary regulatory catalysts.

Key Financial Metrics

EPS
−$0.60
est −$0.56 · -7.1%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss widened to $96.4M in Q2 2026 from $73.5M in Q2 2025, driven by increased R&D ($70.8M vs $62.2M) and G&A ($31.8M vs $13.4M) as the company builds commercial infrastructure
  • Cash, equivalents and marketable securities stood at $792.3M as of June 30, 2026; pro forma cash of $865.9M including $73.6M in ATM proceeds
  • EPS of $-0.60 missed consensus estimate of $-0.56 by 6.2%, a modest miss for a pre-revenue biotech where EPS is driven by expense timing, not business deterioration
  • NDA for bezuclastinib in GIST accepted with priority review, PDUFA date of November 30, 2026
  • NDA for bezuclastinib in NonAdvSM submitted, PDUFA date of December 30, 2026; NDA for AdvSM submitted June 30, 2026
  • Inducement grants of 226,700 options and 189,700 RSUs made to 59 new commercial employees on August 4 and August 10, 2026

Financial Impact

Net loss $96.4M; operating expenses $102.6M; no revenue; cash burn rate approximately $100M/quarter

net_losscash_positionoperating_expenses

Risk Factors

  • FDA could issue Complete Response Letter for bezuclastinib in GIST or NonAdvSM, delaying or denying approval
  • Commercial execution risk: if approved, investor expectations around launch trajectory may be high given the $7.2B market cap
  • Cash burn may accelerate with commercial buildout; post-quarter ATM filing suggests potential need for additional capital beyond late 2028

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3341783

Track record

13 reports on COGT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Viewing Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026